• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 4, 2015

View Archived Issues

Durect to NASH-ville and beyond? 'Lucky' firm with metabolic NCE still in drug-delivery game

Durect Corp., better known as a drug delivery firm, disclosed a successful phase I trial with DUR-928, described as an endogenous small-molecule new chemical entity that could work in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), as well as acute kidney injury. Read More

NIH budget bump dependent on the future of sequestration

Recognizing the NIH's role in driving biomedical advances and the economy, a House appropriations subcommittee seemed supportive Tuesday of a $1 billion bump in NIH funding – provided Congress does away with the threat of sequestration. Read More

IPO pace likely to slow in 2015, says VC, banker

SAN FRANCISCO – In the wake of last year's hot IPO market, this year's climate is likely to be significantly cooler, giving way to between 25 and 30 U.S. biopharma IPOs, projected venture captialist Brent Ahrens and banker Jennifer Jarrett during a "crystal ball" panel at the CalBio 2015 conference, a gathering of California industry mavens organized by BayBio and Biocom, the state's biggest life sciences trade associations. Read More

Eddingpharm flexes CDV muscle in $169M Amarin deal for Vascepa

SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China. Read More

Information gaps persist in EMA drug assessments, IQWiG study claims

DUBLIN – A newly published analysis from Germany's main health technology assessment agency, the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), concluded that the benefit assessment process Germany introduced for new drugs in 2011 has narrowed the information gap on new medicines and provided a fuller understanding of their benefits and risks than that available from other regulatory and academic sources. Read More

Taimed's ibalizumab wins FDA breakthrough status in HIV; BLA coming soon

HONG KONG – Known already as the first China-manufactured biologic used in U.S. trials, HIV candidate ibalizumab (TMB-355) won FDA breakthrough therapy designation, which could substantially accelerate the product's launch. Read More

Blueprint Medicines to work with Alexion on rare genetic disease

Blueprint Medicines Corp. will bank $15 million as an up-front payment from Cheshire, Conn.-based Alexion Pharmaceuticals Inc. as a kick-off to their strategic collaboration that will center on an undisclosed activated kinase target, which is the cause of a rare genetic disease. Read More

Regulatory front

Sens. Chris Coons (D-Del.), Dick Durbin (D-Ill) and Mazie Hirono (D-Hawaii) introduced the STRONG Patents Act Tuesday to protect individual inventors and research-intensive companies from frivolous patent lawsuits and to level the playing field between small inventors and large companies. Read More

Earnings

Salix Pharmaceuticals Ltd., of Raleigh, N.C., reported total net product revenues for the fourth quarter of $13 million, compared to $238 million for the fourth quarter of 2013. Non-GAAP net loss for the quarter was $167 million, or $2.61 per share, far greater than the expected 25-cent-per-share loss predicted by analysts. Read More

Stock movers

Read More

Financings

Curis Inc., of Lexington, Mass., said it closed its public offering, selling 25.1 million shares at $2.75 apiece, including the exercise in full by underwriters to purchase an additional 3.3 million shares. Read More

Other news to note

Denovo Biopharma LLC, of San Diego, said it exclusively licensed pomaglumetad methionil, a late-stage mGlu2/3 receptor agonist, from Eli Lilly and Co., of Indianapolis, gaining all rights to develop, manufacture and commercialize the drug globally, including transfer of all intellectual property and other rights, data and information. Read More

In the clinic

Melior Pharmaceuticals Inc., of Exton, Pa., randomized the first patient into treatment arms of a phase II study aimed at evaluating the efficacy of MLR-1023 in type 2 diabetes. Read More

Pharma: Other news to note

Pfizer Inc., of New York, said the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 and older. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe